• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Factors influencing elimination and distribution of fleroxacin: metaanalysis of individual data from 10 pharmacokinetic studies.影响氟罗沙星消除和分布的因素:来自10项药代动力学研究的个体数据的荟萃分析。
Antimicrob Agents Chemother. 1996 Mar;40(3):575-80. doi: 10.1128/AAC.40.3.575.
2
First population pharmacokinetic analysis showing increased quinolone metabolite formation and clearance in patients with cystic fibrosis compared to healthy volunteers.首次群体药代动力学分析显示,与健康志愿者相比,囊性纤维化患者的喹诺酮类代谢产物生成和清除增加。
Eur J Pharm Sci. 2018 Oct 15;123:416-428. doi: 10.1016/j.ejps.2018.07.054. Epub 2018 Aug 1.
3
Bioavailability of ciprofloxacin and fleroxacin: results of a preliminary investigation in healthy adult Nigerian male volunteers.环丙沙星和氟罗沙星的生物利用度:尼日利亚成年健康男性志愿者的初步调查结果。
Biol Pharm Bull. 2000 Aug;23(8):968-72. doi: 10.1248/bpb.23.968.
4
Pharmacokinetics of fleroxacin after multiple oral dosing in patients receiving regular hemodialysis.接受定期血液透析患者多次口服氟罗沙星后的药代动力学
Antimicrob Agents Chemother. 1996 Aug;40(8):1903-9. doi: 10.1128/AAC.40.8.1903.
5
Influence of sex on the pharmacokinetic interaction of fleroxacin and ciprofloxacin with caffeine.性别对氟罗沙星和环丙沙星与咖啡因药代动力学相互作用的影响。
Clin Pharmacokinet. 2003;42(11):985-96. doi: 10.2165/00003088-200342110-00004.
6
Single-dose pharmacokinetic study of ciprofloxacin and fleroxacin in healthy adult Nigerian volunteers.环丙沙星和氟罗沙星在尼日利亚健康成年志愿者中的单剂量药代动力学研究。
Chemotherapy. 1998 Nov-Dec;44(6):369-76. doi: 10.1159/000007146.
7
Single-dose pharmacokinetics of oral fleroxacin in bacteremic patients.口服氟罗沙星在菌血症患者中的单剂量药代动力学
Antimicrob Agents Chemother. 1994 Jun;38(6):1219-24. doi: 10.1128/AAC.38.6.1219.
8
Pharmacokinetics of oral fleroxacin in male and premenopausal female volunteers.口服氟罗沙星在男性和绝经前女性志愿者体内的药代动力学。
Antimicrob Agents Chemother. 1996 Mar;40(3):789-91. doi: 10.1128/AAC.40.3.789.
9
Disposition of fleroxacin, a new trifluoroquinolone, and its metabolites. Pharmacokinetics in elderly patients.新型三氟喹诺酮类药物氟罗沙星及其代谢产物的处置。老年患者的药代动力学。
Clin Pharmacokinet. 1990 Jul;19(1):80-8. doi: 10.2165/00003088-199019010-00006.
10
Pharmacokinetics and body fluid penetration of fleroxacin in healthy volunteers.氟罗沙星在健康志愿者体内的药代动力学及体液渗透情况
J Antimicrob Chemother. 1988 Oct;22 Suppl D:155-67. doi: 10.1093/jac/22.supplement_d.155.

引用本文的文献

1
Decreased maximal aerobic capacity in pediatric chronic kidney disease.小儿慢性肾脏病患者最大有氧能力下降。
J Am Soc Nephrol. 2008 Mar;19(3):624-30. doi: 10.1681/ASN.2007070773. Epub 2008 Jan 9.
2
The influence of sex on pharmacokinetics.性别对药代动力学的影响。
Clin Pharmacokinet. 2003;42(2):107-21. doi: 10.2165/00003088-200342020-00001.
3
How important are gender differences in pharmacokinetics?药代动力学中的性别差异有多重要?
Clin Pharmacokinet. 2002;41(5):329-42. doi: 10.2165/00003088-200241050-00002.

本文引用的文献

1
Single-dose pharmacokinetics of oral fleroxacin in bacteremic patients.口服氟罗沙星在菌血症患者中的单剂量药代动力学
Antimicrob Agents Chemother. 1994 Jun;38(6):1219-24. doi: 10.1128/AAC.38.6.1219.
2
Should clearance be normalised to body surface or to lean body mass?清除率应按体表面积还是去脂体重进行标准化?
Br J Clin Pharmacol. 1981 May;11(5):523-6. doi: 10.1111/j.1365-2125.1981.tb01163.x.
3
Alternative approaches to estimation of population pharmacokinetic parameters: comparison with the nonlinear mixed-effect model.群体药代动力学参数估计的替代方法:与非线性混合效应模型的比较。
Drug Metab Rev. 1984;15(1-2):265-92. doi: 10.3109/03602538409015066.
4
Aging, total body potassium, fat-free mass, and cell mass in males and females between ages 18 and 85 years.18至85岁男性和女性的衰老、全身钾含量、去脂体重和细胞质量。
J Gerontol. 1972 Oct;27(4):438-43. doi: 10.1093/geronj/27.4.438.
5
Analysis of pharmacokinetic data using parametric models. III. Hypothesis tests and confidence intervals.
J Pharmacokinet Biopharm. 1986 Oct;14(5):539-55. doi: 10.1007/BF01059660.
6
Fleroxacin: in-vitro activity worldwide against 20,807 clinical isolates and comparison to ciprofloxacin and norfloxacin.氟罗沙星:全球范围内对20807株临床分离菌的体外活性及与环丙沙星和诺氟沙星的比较
J Antimicrob Chemother. 1988 Oct;22 Suppl D:3-17. doi: 10.1093/jac/22.supplement_d.3.
7
Metabolism of fleroxacin in man.氟罗沙星在人体内的代谢。
J Antimicrob Chemother. 1988 Oct;22 Suppl D:169-78. doi: 10.1093/jac/22.supplement_d.169.
8
Pharmacokinetics and body fluid penetration of fleroxacin in healthy volunteers.氟罗沙星在健康志愿者体内的药代动力学及体液渗透情况
J Antimicrob Chemother. 1988 Oct;22 Suppl D:155-67. doi: 10.1093/jac/22.supplement_d.155.
9
Single and multiple dose pharmacokinetics of fleroxacin.氟罗沙星的单剂量和多剂量药代动力学
J Antimicrob Chemother. 1988 Oct;22 Suppl D:145-54. doi: 10.1093/jac/22.supplement_d.145.
10
Clinical pharmacokinetics and tolerance of fleroxacin in healthy male volunteers.氟罗沙星在健康男性志愿者中的临床药代动力学及耐受性
J Antimicrob Chemother. 1988 Oct;22 Suppl D:133-44. doi: 10.1093/jac/22.supplement_d.133.

影响氟罗沙星消除和分布的因素:来自10项药代动力学研究的个体数据的荟萃分析。

Factors influencing elimination and distribution of fleroxacin: metaanalysis of individual data from 10 pharmacokinetic studies.

作者信息

Reigner B G, Welker H A

机构信息

Department of Clinical Pharmacology, F. Hoffmann-La Roche Ltd., Basel, Switzerland.

出版信息

Antimicrob Agents Chemother. 1996 Mar;40(3):575-80. doi: 10.1128/AAC.40.3.575.

DOI:10.1128/AAC.40.3.575
PMID:8851573
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC163160/
Abstract

A metaanalysis was conducted on data from 172 subjects (healthy volunteers and uninfected patients) included in 10 pharmacokinetic studies of fleroxacin after oral administration. The objectives of this analysis were (i) to estimate the typical values of two key pharmacokinetic parameters, clearance over systemic availability (CL/F) and volume of distribution over systemic availability (V/F), after the administration of therapeutic doses and (ii) to study qualitatively and quantitatively the factors which influence the elimination and distribution of fleroxacin. The main pharmacokinetic parameters, CL/F and V/F, were analyzed separately by a standard two-stage approach. The covariates investigated were predicted creatinine clearance (CLCR), age, gender, body surface area, body weight, and lean body weight (LBW). The predicted CL/F and V/F were 83.5 ml/min and 101 liters, respectively, for a typical male subject (CLCR, 70 ml/min; LBW, 54 kg; age, 54 years). Modeling of CL/F indicated that this parameter increases linearly with CLCR, decreases linearly with age, and is 10.8 ml/min lower in females than in males. The best model for V/F showed a linear increase with LBW and a linear decrease with age. V/F was found to be 20.4 liters greater in males than in females. In conclusion, this metaanalysis has shown that CLCR, age, and gender influence the elimination of fleroxacin from the body, whereas V/F is influenced by LBW, age, and gender.

摘要

对10项口服氟罗沙星药代动力学研究中纳入的172名受试者(健康志愿者和未感染患者)的数据进行了荟萃分析。该分析的目的是:(i)估计治疗剂量给药后两个关键药代动力学参数,即清除率与全身可用性之比(CL/F)和分布容积与全身可用性之比(V/F)的典型值;(ii)定性和定量研究影响氟罗沙星消除和分布的因素。主要药代动力学参数CL/F和V/F采用标准的两阶段方法分别进行分析。研究的协变量包括预测的肌酐清除率(CLCR)、年龄、性别、体表面积、体重和瘦体重(LBW)。对于典型男性受试者(CLCR,70 ml/min;LBW,54 kg;年龄,54岁),预测的CL/F和V/F分别为83.5 ml/min和101升。CL/F的模型表明,该参数随CLCR呈线性增加,随年龄呈线性降低,女性比男性低10.8 ml/min。V/F的最佳模型显示随LBW呈线性增加,随年龄呈线性降低。发现男性的V/F比女性大20.4升。总之,该荟萃分析表明,CLCR、年龄和性别影响氟罗沙星从体内的消除,而V/F受LBW、年龄和性别的影响。